Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device maker, citing concerns over its prospects in the market for Transcatheter Aortic Valve Replacement (TAVR).

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the fourth quarter, Wedgewood Composite’s net return was 5.

Following these transactions, Bobo holds 46,935.7184 shares directly, with additional holdings in indirect accounts, including 38,616.6145 shares in a 401(k) and 135,152 shares held by a trust. The company maintains robust financial health with a current ratio of 3.